Skip to content
The Nexus
DossierENTITY

nivolumab

Coverage of nivolumab in the Nexus archive.

Earliest in view: Apr 29 · 00:00 UTCMost recent: Apr 29 · 00:00 UTC
Co-mentioned in this coverage
NIVIPIT trialorganization1ipilimumabtopic1Natureorganization1anti-PD1topic1anti-CTLA4topic1intratumoural administrationtopic1intravenous deliverytopic1
Recent coverage
  • HEALTHApr 29 · 00:00 UTCNATURE NEWS
    Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1

    The phase 1b NIVIPIT trial demonstrated that combining intratumoural ipilimumab (anti-CTLA4) with intravenous nivolumab (anti-PD1) improves safety and efficacy compared to intravenous delivery alone. The study, published in Nature, highlights a novel approach to cancer immunotherapy.